Quốc gia: New Zealand
Ngôn ngữ: Tiếng Anh
Nguồn: Medsafe (Medicines Safety Authority)
Pemetrexed disodium 562.43mg (as 2.5-hydrate, equivalent to pemetrexed 500 mg)
Pfizer New Zealand Limited
Pemetrexed disodium 562.43 mg (as 2.5-hydrate, equivalent to pemetrexed 500 mg)
500 mg
Powder for infusion
Active: Pemetrexed disodium 562.43mg (as 2.5-hydrate, equivalent to pemetrexed 500 mg) Excipient: Hydrochloric acid Mannitol Sodium hydroxide
Vial, glass, clear, Type I, with grey bromobutyl rubber closure, Al seal, flip off top, 50 mL, 1 dose unit
Prescription
Prescription
Chongqing Pharmaceutical Research Institute
DBL™ Pemetrexed (as disodium) powder for infusion, in combination with cisplatin, is indicated for the treatment of patients with malignant pleural mesothelioma.
Package - Contents - Shelf Life: Vial, glass, clear, Type I, with grey bromobutyl rubber closure, Al seal, flip off top, 50 mL - 1 dose units - 36 months from date of manufacture stored at or below 25°C
2012-01-06
[Medsafe: New Zealand Medicines and Medical Devices Safety Authority] [/index.asp] MEDSAFE [/index.asp] ------------------------- NEW ZEALAND MEDICINES AND MEDICAL DEVICES SAFETY AUTHORITY [/index.asp] Search: * Medicines [/Medicines/medicines-landing.asp] * Medicine Information [/Medicines/medicine-information.asp] * Approval Process [/Medicines/regulatory-approval-process.asp] * Regulatory Guidance [/Medicines/regulatory-landing.asp] * Clinical Trials [/Medicines/clinical-trials.asp] * Classification [/profs/class/clascon.asp] * Manufacturing [/Medicines/manufacturing.asp] * Devices [/devices/devices-landing.asp] * WAND [/regulatory/DevicesNew/3WAND.asp] * Regulatory Guidance [/regulatory/DevicesNew/industry.asp] * Surgical Mesh [/devices/Surgical%20Mesh/Landing.asp] * Safety Information [/regulatory/DevicesNew/safety.asp] * Product Recalls [/hot/ProductRecallInformation/ProductRecallHome.asp] * Device Information [/devices/education-and-information.asp] * Safety [/safety/safety-landing.asp] * Safety Information [/safety/education-and-information.asp] * Product Recalls [/hot/ProductRecallInformation/ProductRecallHome.asp] * Safety Communications [/safety/alerts.asp] * Adverse Reaction Reporting [/safety/ADR-reporting.asp] * Compliance [/compliance/compliance-landing.asp] * Unapproved Medicines [/profs/RIss/unapp.asp] * Recalls [/hot/ProductRecallInformation/ProductRecallHome.asp] * Marketing [/compliance/advertising.asp] * Importing Medicines [/compliance/importing-medicines.asp] * DG Statements [/publications/dg-statements.asp] * Manufacturing [/Medicines/manufacturing.asp] * Publications [/publications/publications-landing.asp] * Media [/hot/MediaContents.asp] * Prescriber Update [/publications/prescriber-update.asp] * OIA Releases [/publications/oia.asp] * Consultations [/consultations/consultations-landing.asp] * Current [/consultations/current.asp] * Closed [/consultations/closed.asp] * Outcomes [/consultations/outcome.asp] * Committees [/committees/committees-landing.asp] * Medicines Classification [/comm Đọc toàn bộ tài liệu